Zacks: Brokerages Expect Lion Biotechnologies, Inc. (IOVA) to Post -$0.35 Earnings Per Share
Analysts predict that Lion Biotechnologies, Inc. (NASDAQ:IOVA) will post ($0.35) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Lion Biotechnologies’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.29). Lion Biotechnologies posted earnings per share of ($0.17) in the same quarter last year, which would indicate a negative year over year growth rate of 105.9%. The company is scheduled to issue its next quarterly earnings results on Friday, November 3rd.
According to Zacks, analysts expect that Lion Biotechnologies will report full-year earnings of ($1.42) per share for the current financial year, with EPS estimates ranging from ($1.48) to ($1.30). For the next fiscal year, analysts forecast that the business will report earnings of ($1.47) per share, with EPS estimates ranging from ($1.66) to ($1.23). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Lion Biotechnologies.
A number of analysts recently weighed in on the company. Zacks Investment Research upgraded Lion Biotechnologies from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Lion Biotechnologies in a research report on Wednesday, June 7th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a research report on Tuesday, June 6th. FBR & Co restated a “buy” rating on shares of Lion Biotechnologies in a research report on Thursday, May 18th. Finally, Rodman & Renshaw assumed coverage on Lion Biotechnologies in a research report on Wednesday, May 10th. They issued a “buy” rating and a $13.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Lion Biotechnologies presently has an average rating of “Buy” and a consensus price target of $13.88.
Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $103,000. Parametric Portfolio Associates LLC bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $125,000. People s United Financial Inc. bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $143,000. Voya Investment Management LLC bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $208,000. Finally, ProShare Advisors LLC bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $270,000. Hedge funds and other institutional investors own 76.00% of the company’s stock.
Lion Biotechnologies (NASDAQ:IOVA) traded up 4.35% during midday trading on Monday, reaching $6.00. 1,507,385 shares of the company’s stock traded hands. Lion Biotechnologies has a 52-week low of $4.45 and a 52-week high of $8.61. The company’s market cap is $376.12 million. The stock has a 50-day moving average of $5.59 and a 200 day moving average of $6.45.
About Lion Biotechnologies
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.